Literature DB >> 34791428

Consensus core clinical data elements for meningiomas (v2021.1).

Farshad Nassiri1,2,3, Justin Z Wang1,2,3, Karolyn Au4, Jill Barnholtz-Sloan5, Michael D Jenkinson6, Kate Drummond7, Yueren Zhou8, James M Snyder9, Priscilla Brastianos10, Thomas Santarius11, Suganth Suppiah1,2,3, Laila Poisson8, Francesco Gaillard12, Mark Rosenthal13, Timothy Kaufmann14, Derek S Tsang3, Kenneth Aldape15, Gelareh Zadeh1,2,3.   

Abstract

BACKGROUND: With increasing molecular analyses of meningiomas, there is a need to harmonize language used to capture clinical data across centers to ensure that molecular alterations are appropriately linked to clinical variables of interest. Here the International Consortium on Meningiomas presents a set of core and supplemental meningioma-specific common data elements (CDEs) to facilitate comparative and pooled analyses.
METHODS: The generation of CDEs followed the 4-phase process similar to other National Institute of Neurological Disorders and Stroke (NINDS) CDE projects: discovery, internal validation, external validation, and distribution.
RESULTS: The CDEs were organized into patient- and tumor-level modules. In total, 17 core CDEs (10 patient level and 7 tumor level) as well as 14 supplemental CDEs (7 patient level and 7 tumor level) were defined and described. These CDEs are now made publicly available for dissemination and adoption.
CONCLUSIONS: CDEs provide a framework for discussion in the neuro-oncology community that will facilitate data-sharing for collaborative research projects and aid in developing a common language for comparative and pooled analyses. The meningioma-specific CDEs presented here are intended to be dynamic parameters that evolve with time and The Consortium welcomes international feedback for further refinement and implementation of these CDEs.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  clinical trials; consensus; core data elements; meningioma; retrospective studies

Mesh:

Year:  2022        PMID: 34791428      PMCID: PMC9071284          DOI: 10.1093/neuonc/noab259

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  164 in total

1.  Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy.

Authors:  Jacob S Witt; Hima B Musunuru; R Adam Bayliss; Steven P Howard
Journal:  J Neurooncol       Date:  2018-11-03       Impact factor: 4.130

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 3.  Radiation induced meningioma with a short latent period following high dose cranial irradiation - case report and literature review.

Authors:  Ajay Choudhary; Satyajit Pradhan; Mohammad Fakhrul Huda; Sureswar Mohanty; Mohan Kumar
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

4.  Radiation-induced meningioma.

Authors:  A Dweik; J Maheut-Lourmiere; E Lioret; M Jan
Journal:  Childs Nerv Syst       Date:  1995-11       Impact factor: 1.475

Review 5.  Radiation-induced meningioma.

Authors:  Felix Umansky; Yigal Shoshan; Guy Rosenthal; Shifra Fraifeld; Sergey Spektor
Journal:  Neurosurg Focus       Date:  2008       Impact factor: 4.047

6.  TERT Promoter Mutations and Risk of Recurrence in Meningioma.

Authors:  Felix Sahm; Daniel Schrimpf; Adriana Olar; Christian Koelsche; David Reuss; Juliane Bissel; Annekathrin Kratz; David Capper; Sebastian Schefzyk; Thomas Hielscher; Qianghu Wang; Erik P Sulman; Sebastian Adeberg; Arend Koch; Ali Fuat Okuducu; Stefanie Brehmer; Jens Schittenhelm; Albert Becker; Benjamin Brokinkel; Melissa Schmidt; Theresa Ull; Konstantinos Gousias; Almuth Friederike Kessler; Katrin Lamszus; Jürgen Debus; Christian Mawrin; Yoo-Jin Kim; Matthias Simon; Ralf Ketter; Werner Paulus; Kenneth D Aldape; Christel Herold-Mende; Andreas von Deimling
Journal:  J Natl Cancer Inst       Date:  2015-12-13       Impact factor: 13.506

7.  Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.

Authors:  Chenyang Wang; Tania B Kaprealian; John H Suh; Charlotte D Kubicky; Jeremy N Ciporen; Yiyi Chen; Jerry J Jaboin
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

Review 8.  EANO guidelines for the diagnosis and treatment of meningiomas.

Authors:  Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller
Journal:  Lancet Oncol       Date:  2016-08-30       Impact factor: 41.316

9.  A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas.

Authors:  Daniel J Ferraro; Ryan K Funk; John William Blackett; Michelle R Ju; Todd A DeWees; Michael R Chicoine; Joshua L Dowling; Keith M Rich; Robert E Drzymala; Imran Zoberi; Joseph R Simpson; Jerry J Jaboin
Journal:  Radiat Oncol       Date:  2014-01-27       Impact factor: 3.481

Review 10.  The Role of Merlin/NF2 Loss in Meningioma Biology.

Authors:  Sungho Lee; Patrick J Karas; Caroline C Hadley; James C Bayley V; A Basit Khan; Ali Jalali; Alex D Sweeney; Tiemo J Klisch; Akash J Patel
Journal:  Cancers (Basel)       Date:  2019-10-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.